
Results of the 2001 T-Lymphocyte Immunophenotyping Questionnaire Survey Mailed to Laboratories Participating in the Model Performance Evaluation Program



### T-Lymphocyte Immunophenotyping by Multi-Platform and Single-Platform Methods



U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service Centers for Disease Control and Prevention



Report of results for a 2001 T-lymphocyte Immunophenotyping (TLI) laboratory questionnaire survey mailed to laboratories participating in the Model Performance Evaluation Program, Centers for Disease Control and Prevention (CDC).

Production of this report was coordinated in CDC by:
Public Health Practice Program Office Edward L. Baker, M.D., M.P.H.
Director
Division of Laboratory Systems Robert Martin, Dr.P.H.
Director
Laboratory Practice Assessment Branch Barbara A. Slade, M.D.
Chief
The material in this report was developed and prepared by:
Model Performance Evaluation Program (MPEP) Barbara A. Slade, M.D.
Chief
MPEP TLI Performance Evaluation G. David Cross, M.S.
MPEP TLI Project Coordinator

Use of trade names and commercial sources is for identification only and does not constitute endorsement by the Public Health Service or the U.S. Department of Health and Human Services.

Information about this report should be addressed to the Model Performance Evaluation Program by calling (770) 488-8091 or (770) 488-8137.

#### **Introductory Comments**

The aggregate results from a mailed questionnaire survey conducted by the Model Performance Evaluation Program (MPEP) in May 2001 of laboratories in the United States performing T-lymphocyte immunophenotyping (TLI) are presented in the following figures and tables. Of the 300 laboratories receiving this survey (four enrolled laboratories chose not to receive the survey), 246 (82.0%) reported results. The "N" numbers appearing in each figure or table reflect the total number of laboratories responding to the specific question. For multiple response questions, the total number of responses may exceed the actual number of laboratories responding to that specific question.

The map located on page 2 reflects the enrollment in the MPEP TLI program at the time this survey was mailed, and may not reflect the current enrollment in this program.

The primary classification of all the laboratories in the MPEP TLI program at the time the survey was mailed is shown in the top figure on page 4. The primary classification of only those laboratories responding to the survey is shown in the bottom figure on the same page. The further classifications of the responding laboratories are shown in the responses for questions 5(a)-5(e).

Please note that wording for questions 6 and 7, regarding the education and certification requirements of the laboratory director and supervisor, reflect current regulatory requirements related to the Clinical Laboratory Improvement Amendments of 1988 (CLIA '88), as published in CFR 42, Part 493.

The term "single-platform method" was defined to be those methods for obtaining absolute CD4<sup>+</sup> T-cell counts using a single-instrument, for example, FACSCount or Imagn 2000, or laboratory test, for example, TRAx CD4 or Manual CD4 Count kit. The term "multi-platform method" was defined to be those methods that derive absolute CD4<sup>+</sup> T-cell counts by using the percent CD4<sup>+</sup> T-cells obtained from a flow cytometer in combination with the absolute lymphocyte count obtained from a hematology instrument.


Responses to question 8 reflect the amount of experience necessary to perform either single-platform or multi-platform methods.

Question 27 requested information regarding the monoclonal antibody manufacturer associated with reagents for each of the cell marker combinations routinely used for performing TLI. The first two pages of results for this question, pages 37-38, show the reagents used for single-color, two-color, three-color, and four-color tests. A summary of monoclonal antibody reagents used by participant laboratories is shown on page 39. Pages 40 through 43 show the monoclonal antibody reagent panels used by the participant laboratories.


Question 44 requested information regarding the price charged for TLI performed by single-platform or multi-platform methods.

Responses to Question 45 reflect the external proficiency testing programs in which participant laboratories are enrolled.


Questions 46 and 47 requested information regarding the surrogate-marker tests and the other tests for HIV infection which are performed by participant laboratories.








#### Primary Classification of MPEP TLI Testing Laboratories



#### **Total Number of Laboratories in TLI Program**

Primary Classification of Laboratory


#### Laboratories Responding to Questionnaire Survey




Frequency of Laboratories Responding

Primary Classification of Laboratory


5.(a) If the laboratory type shown on your mailing label (located on page one) is BLOOD BANK, please <u>further describe</u> your TLI testing laboratory (Check <u>all</u> that apply within your Blood Bank laboratory classification.):




5.(b) If the laboratory type shown on your mailing label (located on page one) is HOSPITAL, please <u>further describe</u> your TLI testing laboratory (Check <u>all</u> that apply within your Hospital laboratory classification.):




5.(c) If the laboratory type shown on your mailing label (located on page one) is HEALTH DEPARTMENT, please <u>further describe</u> your TLI testing laboratory (Check <u>all</u> that apply within your Health Department laboratory classification.):




5.(d) If the laboratory type shown on your mailing label (located on page one) is INDEPENDENT, please <u>further describe</u> your TLI testing laboratory (Check <u>all</u> that apply within your Independent laboratory classification.):




5.(e) If the laboratory type shown on your mailing label (located on page one) is OTHER, please <u>further describe</u> your TLI testing laboratory (Check <u>all</u> that apply within your Other laboratory classification.):



#### Please choose from the list below the *highest academic degree* that has 6.(a) been awarded to your Laboratory Director and Laboratory Supervisor (Choose only one degree for each person.):




#### If your Laboratory Director or Laboratory Supervisor has a degree other 6.(b) than M.D. or D.O., please indicate the academic discipline in which the degree was awarded (Check all that apply.):




Frequency of Laboratories Responding

# 6.(c) What board certifications have been awarded to your <u>Laboratory Director</u>? (Check <u>all</u> that apply.)




# 6.(d) Please indicate the years of experience your <u>Laboratory Director</u> has in directing or supervising laboratory testing (Round off to the nearest whole number.):




Frequency of Laboratories Responding


6.(e) Is your <u>Laboratory Supervisor</u> available to provide supervision on-site?




7.(a) Does your laboratory require that personnel who perform TLI (operate a flow cytometer and analyze resultant data) have a <u>minimum educational</u> <u>degree</u>?




## 7.(b) What minimum educational degree is required of your TLI testing personnel? (Choose only <u>one</u> degree.)




 7.(c) Does your laboratory require that your TLI testing personnel have <u>certification by a professional organization</u>? (Do not include licensing by city, state, or county.)



7.(d) Please check the *professional organizations* that have awarded the required *certification* to your *TLI testing personnel* (Check <u>all</u> that apply.):




8. On average, how many months of experience do your personnel need to become proficient in performing TLI and analyzing the resultant data? (Indicate number of months of experience needed only for those methods currently in use in your laboratory. Round off to the nearest whole number.)




Single-Platform


Frequency of Laboratories Responding




CDC Model Performance Evaluation Program 13 May 2001 TLI Survey 9.(a) Does your laboratory require that personnel who perform TLI have training?




9. (b) What training must your laboratory personnel complete before they are considered qualified to perform TLI? (Check <u>all</u> that apply.)



# 10.(a) On average, how many TLI specimens are tested in your laboratory in a <u>month</u>? (Number of single patient and/or blood donor specimens, <u>not</u> tests. Round off to the nearest whole number.)




#### 10.(b) How many TLI specimens were tested in your laboratory in the last <u>year</u>? (Number of single patient and/or blood donor specimens, <u>not</u> tests. Round off to the nearest whole number.)




Number Samples Tested Last Year

10.(c) Has the number of requests per month for TLI to be performed by your laboratory increased, decreased, or stayed the same compared to twelve months ago? (Choose only <u>one</u>.)



# 11. In the last year, what percentage of your TLI specimens have come from patients known by your laboratory to be HIV-infected? (Round off to the nearest whole number.)




Frequency of Laboratories Responding

16 CDC Model Performance Evaluation Program May 2001 TLI Survey


12.(a) If written instructions are provided to collection site personnel for collecting, labeling, and transporting TLI specimens, who provides these instructions? (Check <u>all</u> that apply.)

Type of Instruction	Instructions NOT Provided	Testing Laboratory	Associated Institution	Person Ordering Test	Other	N =
Collecting	3	208	42	12	4	233
Labeling	5	200	46	12	3	230
Transporting	4	205	41	11	2	231


#### 12.(b) Where are your specimens collected for TLI? (Choose only one.)




## 12.(c) When your laboratory tests TLI specimens that are collected off-site, where are the specimens collected? (Check <u>all</u> that apply.)




## 12.(d) How are the off-site TLI specimens delivered to your laboratory? (Check <u>all</u> that apply.)



## 12.(e) At what temperature are TLI specimens transported to your laboratory? (Check <u>all</u> that apply.)




# 13. On average, how many hours does it take from the time a TLI specimen is <u>collected</u> until the time it is <u>delivered</u> to your laboratory? (Round off to the nearest whole number.)




Frequency of Laboratories Responding


14.(a) Are the procedures your laboratory uses for labeling a suspected HIV-1-positive specimen different from the procedures you use for other specimens?




14.(b) <u>Universal precautions</u> assume that <u>all</u> blood and body fluids are <u>potentially</u> infectious for blood borne pathogens. How often do your laboratory employees follow <u>universal precautions</u> when handling specimens for TLI? (Choose only <u>one</u>.)




15. Where is the hematology testing (e.g., complete blood count [CBC]) for your laboratory's TLI specimens usually performed? (Choose only <u>one</u>.)



## 16.(a) Does your laboratory use TLI specimen collection criteria to determine whether or not a specimen is acceptable for TLI?




16.(b) What specimen collection criteria are used at your laboratory to determine whether or not a specimen is acceptable for TLI? (Check <u>all</u> that apply.)




# 17. At what temperatures does your laboratory store TLI specimens until they are processed? (Check <u>all</u> that apply.)

Type of Specimen	Room Temperature	2 - 10 °C	Other Temperature	N =
Whole Blood	240	2	1	243
Separated Cells	20	30	2	50
Other	8	8	1	15


## 18. When did your laboratory begin performing TLI? (Please indicate month and year only for those methods currently in use in your laboratory.)








#### 19. Does your laboratory perform TLI using a flow cytometry instrument?




## 20.(a) How many flow cytometer operators actually performed TLI in your laboratory over the last 12 months?




Frequency of Laboratories Responding


20.(b) Do any of your laboratory's flow cytometer operators routinely perform TLI on more than one flow cytometer?



20.(c) Have your flow cytometer operators received training on each of the instruments that they are required to operate?




## 21. What are the quantities and manufacturers of your laboratory's flow cytometers that are used for TLI?




Frequency of Laboratories Responding

## 21. What are the quantities and manufacturers of your laboratory's hematology analyzer that are used for TLI?




Frequency of Laboratories Responding

22. Can multicolor analysis techniques (two or more markers tagged with different color fluorochromes as a single test) be used to perform TLI on any of the flow cytometry instruments you indicated?




23. On average, how many hours is a specimen stored at your laboratory before it is stained for TLI? (If the specimen is processed immediately upon receipt, please indicate 0 hours, otherwise, round off to the nearest whole number.)




Frequency of Laboratories Responding

24.(a) Is testing for viability of TLI specimens performed by your laboratory?




#### 24.(b) How is testing for viability performed? (Check all that apply.)




## 24.(c) What is the minimum percent viability acceptable by your laboratory for TLI? (Round off to the nearest whole number.)


Frequency of Laboratories Responding



25.(a) Does your laboratory use a whole blood lysis method for staining TLI specimens?




25.(b) Which lysis method does your laboratory use? (Check <u>all</u> that apply.)





<sup>32</sup> CDC Model Performance Evaluation Program May 2001 TLI Survey

## 25.(c) What sample staining procedure(s) does your laboratory use for TLI? (Check <u>all</u> that apply.)




## 25.(d) Does your laboratory routinely use isotype controls as part of the staining procedure?






# 25.(e) At what temperature does your laboratory routinely perform the staining procedure? (Choose only <u>one</u>.)


25.(f) Does your laboratory fix cells before TLI flow cytometry is performed?






### 25.(g) At what temperature does your laboratory routinely store cells after staining? (Choose only <u>one</u>.)

25.(h) On average, how many <u>hours</u> is a specimen <u>stored</u> at your laboratory after staining before being <u>analyzed</u>? (If the specimen is analyzed immediately after staining, please indicate 0 hours, otherwise, round off to the nearest whole number.)



Frequency of Laboratories Responding





27. Please complete the table below and the tables on the following pages, by choosing from the list below, the monoclonal antibody manufacturer associated with reagents for each cell marker combinations you routinely use for performingTLI.

Monoclonal Antibody Manufacturers Used											
Cell Marker	А	В	С	D	Е	F	G	Н	Ι	J	К
CD3	4	18		1					1		
CD4	4	17		1					1		
CD8	5	15		1					1		
CD19	5	19		1							
CD16	2	14		1							
CD56	3	15		2							
CD56+16	2	15									

Single-color Tests

Two-color Tests Combinations of Monoclonal Antibody Manufacturers Used

Cell Marker	A/A	B/B	C/A	C/C	D/D	I/B	I/I	C/B	A/D	A/B
CD45/CD14	33	48			2	1				
CD3/CD4	21	50			2		1	1		
CD3/CD8	21	51	1		2		1			
CD3/CD19	12	46			2	1				
CD3/CD16	4	14		1	1	1				
CD3/CD56	6	14				1			1	
CD3/CD56+16	2	42				1				1

Manufacturer Key:

A=Coulter/Immunotech B=Becton Dickinson/PharMingen C=Caltag D=Dako E=GenTrak F=Tago G=Olympus H=Ortho I=In-House J=Non-Commercial K=Other

27. Please complete the table below and the tables on the following pages, by choosing from the list below, the monoclonal antibody manufacturer associated with reagents for each of the cell marker combinations you routinely use for performing TLI.

Cell Marker	A/A/A	B/A/A	B/B/B	C/A/A	C/B/B
C45/CD3/CD4	11	1	51		1
C45/CD3/CD8	9	1	45		1
C45/CD3/CD19	3	1	36	1	
C45/CD3/CD56+16	1		31		
CD3/CD4/CD8	11		9		
CD3/CD19/CD16			6		
CD3/CD19/CD56	5		6		
CD3/CD19/CD56+16			5		


#### Three-color Tests Combinations of Monoclonal Antibody Manufacturers Used


Four-color Tests Combinations of Monoclonal Antibody Manufacturers Used

Cell Marker	A/A/A/A	A/A/B/A	A/B/A/B	A/C/A/C	B/A/A/A	B/B/A/A	B/B/A/B	B/B/B/A	B/B/B/B	C/C/C/C
CD45/CD3/CD4/CD8	60				1			1	59	1
CD45/CD3/CD19/CD16	8			1					4	
CD45/CD3/CD19/CD56	40					1			3	
CD45/CD3/CD19/CD56+16	3	1	1				2		49	
CD45/CD3/CD14/CD19	1								4	
CD3/CD4/CD8/CD56+16	1							1	3	


Manufacturer Key:

A=Coulter/Immunotech B=Becton Dickinson/PharMingen C=Caltag D=Dako E=GenTrak F=Tago G=Olympus H=Ortho I=In-House J=Non-Commercial K=Other












### Two-color monoclonal antibody reagent panels used by participant laboratories






# Three-color monoclonal antibody reagent panels used by participant laboratories




### Four-color monoclonal antibody reagent panels used by participant laboratories


### 28.(a) How is the gating set when performing TLI on your flow cytometers? (Choose only <u>one</u>.)




28.(b) Which cell populations are included in the gates for analyses of lymphocyte phenotypes? (Choose only <u>one</u>.)




<sup>44</sup> CDC Model Performance Evaluation Program May 2001 TLI Survey




30.(a) Do you mathematically adjust your phenotype values for isotype control values?




30.(b) How do you adjust your phenotype values? (Choose only one.)



31.(a) How often are normal cell controls used? (Choose only one.)





## 31.(b) Which normal cell control is <u>primarily</u> used in your laboratory? (Choose only <u>one</u>.)



### 47


32. How often do your flow cytometer(s) receive preventive maintenance (e.g., cleaning of optical filters and lenses, and fluidics check)? (Choose only <u>one</u>.)






## 33.(a) How often does your laboratory check the optical alignment of your flow cytometer(s)? (Choose only <u>one</u>.)


33.(b) What types of particles are used by your laboratory to align your flow cytometers? (Check <u>all</u> that apply.)




34.(a) Does your laboratory set fluorescence overlap compensation?




34.(b) What reference materials are used to set fluorescence overlap compensation? (Check <u>all</u> that apply.)




35.(a) What reference materials does your laboratory use to achieve the target conditions for forward angle light scatter (FALS) and fluorescence intensity (FI)? (Check <u>all</u> that apply.)




### 35.(b) Does your laboratory routinely record the instrument settings used to reach the target conditions for FALS?




35.(c) Are these data analyzed to monitor trends or changes in instrument performance?








36.(b) What material(s) does your laboratory use to standardize your flow cytometer(s)? (Check <u>all</u> that apply.)




#### CDC Model Performance Evaluation Program 53 May 2001 TLI Survey


36.(c) Does your laboratory use reference standards to plot standard curves of mean channel fluorescence vs. molecules of equivalent soluble fluorochrome?




36.(d) Does your laboratory maintain written records of the slope, intercept and correlation coefficients of the standard curves?




37. Does your laboratory obtain marker-specific absolute counts (e.g., absolute CD4 count) using a single-platform method?




38. What single-platform method(s) does your laboratory use? (Check <u>all</u> that apply.)




CDC Model Performance Evaluation Program 55 May 2001 TLI Survey 39. Before TLI results are reported, are they routinely reviewed by someone other than the person(s) who performed the tests?




40. What information is included in the report returned to the person or institution initiating the request for TLI? (Check <u>all</u> that apply.)




41. On average, how many days elapse between <u>receipt</u> of the specimen in your laboratory and the time the results of the test are <u>returned</u> to the person or institution initiating the request for TLI? (If results are returned on the same day the specimen is received, please indicate 0 days, otherwise, round off to the nearest whole number.)



### 42. Does your laboratory have procedures for protecting the confidentiality of TLI results?




# 43. On average, how many times in a month does your laboratory receive inquiries from clinicians requesting interpretation of TLI results? (Round off to the nearest whole number.)



Frequency of Laboratories Responding


44.(a) What is the average full price currently charged by your laboratory for TLI for each patient/blood donor sample? (Please indicate the price charged only for those methods currently in use in your laboratory. Round off to the nearest whole dollar.)



**Multi-Platform** 


### Single-Platform

Frequency of Laboratories Responding




<sup>60</sup> CDC Model Performance Evaluation Program May 2001 TLI Survey


44.(b) Has the average full price that your laboratory charges for TLI for each patient/blood donor sample increased, decreased, or stayed the same compared to twelve months ago? (Choose only <u>one</u>.)




44.(c) Do you anticipate the price charged for TLI by your laboratory will increase, decrease, or stay the same in the next twelve months? (Choose only <u>one</u>.)



45.(a) Does your laboratory participate in an external TLI proficiency testing program?




45.(b) In which program(s) does your laboratory participate? Please <u>exclude</u> the CDC Model Performance Evaluation Program, since it is <u>not</u> designed for proficiency testing. (Check <u>all</u> that apply).




62 CDC Model Performance Evaluation Program May 2001 TLI Survey


46.(a) In the last year, has your laboratory performed surrogate-marker tests for TLI in HIV-infected patients?



46.(b) Which surrogate-marker tests did your laboratory perform? (Check <u>all</u> that apply).



47.(a) In the last year, has your laboratory performed other tests for HIV-1 infection?



### 47.(b) Which HIV-1 tests did your laboratory perform? (Check all that apply.)

